This is a randomized, open-label, single dose, crossover, phase 1 trial to evaluate the food effect on pharmacokinetic profiles and safety of CKD-383 in healthy volunteers
Healthy adults aged 19 to 54 years
BMI measurement result is 18.0 kg/m2 to 30 kg/m2
Written informed consent
Other inclusion criteria, as defined in the protocol
who has taken drug metabolism enzyme induction and inhibitory drugs, such as barbitale drugs, within 30 days prior to the start of the trial (Period
Other exclusive criteria, as defined in the protocol